Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novartis AG Common Stock
(NY:
NVS
)
123.81
+0.71 (+0.58%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis AG Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
FDA Flags Weight Loss Risk In ADHD Meds For Kids — J&J, Novartis Escape New Warning
June 30, 2025
The updated label applies to extended-release stimulants prescribed off-label to children under six, following data showing higher drug exposure and side effect rates in that age group.
Via
Stocktwits
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
June 30, 2025
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.
Via
Benzinga
Could This Be the Best High-Dividend ETF to Buy Right Now?
June 30, 2025
Via
The Motley Fool
Topics
ETFs
Economy
Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In
June 27, 2025
Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis.
Via
Stocktwits
Topics
Intellectual Property
Is Novartis Gaining or Losing Market Support?
June 04, 2025
Via
Benzinga
5 Biotech Stocks with Highly Anticipated Pending Results
June 26, 2025
Via
Stocktwits
Topics
Intellectual Property
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
June 26, 2025
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.
Via
Investor's Business Daily
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
June 25, 2025
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.
Via
Benzinga
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
June 25, 2025
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.
Via
Investor's Business Daily
Shuttle Pharma Ramps Up Fight Against Glioblastoma With New Leadership, Promising Clinical Trial, and Bold Innovations
June 23, 2025
Via
Stocktwits
Topics
Cannabis
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
June 23, 2025
Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.
Via
Benzinga
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) – A Solid Value Pick in Pharmaceuticals
June 23, 2025
NOVARTIS AG (NYSE:NVS) offers strong profitability, solid financial health, and an attractive valuation, making it a potential value pick in the pharmaceuticals sector.
Via
Chartmill
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
June 13, 2025
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions.
Via
Benzinga
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
June 12, 2025
Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.
Via
Benzinga
PU Prime Broadens Portfolio with New Global Indices
June 11, 2025
Via
GlobePRwire
Topics
Derivatives
Economy
2 Dividend Growth Stocks to Buy and Hold Forever
June 06, 2025
Via
The Motley Fool
Topics
Intellectual Property
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position
June 05, 2025
Clear Street’s initiated with a $3 price target, highlighting RPT904b as a “potentially best-in-class anti-IgE antibody.”
Via
Stocktwits
Topics
ETFs
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
May 29, 2025
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.
Via
Benzinga
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
June 11, 2025
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
May 28, 2025
Via
Benzinga
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
June 11, 2025
From
FN Media Group LLC
Via
GlobeNewswire
The Smartest Vanguard ETF to Buy With $500 Right Now
May 21, 2025
Via
The Motley Fool
Topics
ETFs
Prediction: This "Magnificent Seven" Stock Will Be the Most Valuable Company in the World in 10 Years
May 16, 2025
This company stands to benefit from the advances in artificial intelligence more than any other business.
Via
The Motley Fool
Topics
Artificial Intelligence
Lazard Transforms Mutual Fund Into IEQ ETF Amid Rising Demand For International Stocks
May 15, 2025
IEQ inherits the portfolio DNA of its mutual fund ancestor, now in the tax-efficient wrapper increasingly favored by investors.
Via
Benzinga
Topics
ETFs
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
May 14, 2025
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Via
Benzinga
Here's My Favorite High-Dividend ETF to Buy Right Now
May 14, 2025
Via
The Motley Fool
Topics
ETFs
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
May 12, 2025
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting...
Via
Stocktwits
Topics
ETFs
Government
Stocks
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
May 12, 2025
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.
Via
Investor's Business Daily
Topics
Government
Stocks
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
May 09, 2025
Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.
Via
Benzinga
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
May 06, 2025
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.